AngioDynamics (ANGO) Tops Q4 EPS by 11c, provides guidance

AngioDynamics (NASDAQ: ANGO) reported Q4 EPS of ($0.05), $0.10 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $70.98 million versus the consensus estimate of $70.9 million.

GUIDANCE:

AngioDynamics sees FY2025 EPS of ($0.38)-($0.42), versus the consensus of ($0.52). AngioDynamics sees FY2025 revenue of $282-288 million, versus the consensus of $292.7 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
• UBS Reiterates Buy Rating on PG&E Corporation (PCG)
• Lululemon (LULU) PT Lowered to $120 at UBS on Expectations for Lowered FY26 Guidance